Longer than a year really - it looks like they are thinking 2H 2020 to hopefully get 2B underway - 12 months dosing means you’re really looking at 2 years+ to completion.
Sarepta’s big move back up has really just filled the gap from the fall when knocked back initially - analysts are thinking they’ll get a 3rd dmd drug approval for casimersen soon as was expected to follow prior.
ATL1102 Blockbuster drug in 2020 and a Coy maker., page-11
-
- There are more pages in this discussion • 173 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
